GSK’s new CEO eyes more dealmaking, intense pipeline inspection Endpoints NewsGSK (FY Results): another step towards mid-term target Hargreaves LansdownGSK delivers strong 2025 performance and re-affirms long-term outlooks GSKGSK’s new CEO looking for $2B to $4B deals ‘hiding in plain sight’ Fierce BiotechGSK sees slower sales growth in 2026 as patent loss looms Sharecast News
